Dr. Reddy’s Aurigene Pharmaceutical Services names CEO

Dr. Reddy's has appointed Akhil Ravi as CEO of its subsidiary Aurigene Pharmaceutical Services.

Since joining Dr. Reddy's in 2018 from McKinsey & Company, Akhil Ravi has served as head of the strategy for services and active pharmaceutical ingredients and headed the sales of APIs in Europe. He also had a brief stint as a plant head. 

[Read more: Dr. Reddy's intros generic Revlimid in Canada]

He has a BTech degree in chemical engineering from IIT Bombay and an MBA from the Indian School of Business.

"Akhil is very well prepared for this role. He was instrumental in growing our API business through product development and an improved service experience for our B2B customers through digital platforms. His strong background in customer service, sales, strategy and management make him an ideal leader for Aurigene, and we look forward to his accomplishments in this new role." said Deepak Sapra, CEO of API and services at Dr. Reddy’s and a member of the board at Aurigene.

[Read more: Dr. Reddy's unveils generic BiCNU]

"Aurigene Pharmaceutical Services is a dynamic partner for global pharma companies. With its integrated services from clinical research up to commercial manufacturing for small and large molecules, it is able to significantly speed up the journey of an NCE/NBE (new chemical and biological rntities) to the patient," Ravi said. "I am very thrilled to join Aurigene and work with the team to serve innovative global pharma and biotech companies."